SCHEMBL1014297

SCHEMBL1014297

CCC(=O)SSC(=O)CC

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
TDP1 Q9NUW8 2/20 0.44
FFAR3 O14843 1/20 0.44
SOAT1 P35610 1/20 0.40
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CES2 O00748 2/20 0.35
CES1 P23141 2/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 2/20 0.33
ALOX15 P16050 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL28496469 0.85 LMNA (0.50) ALDH1A1TDP1FFAR3MEN1KMT2A
SCHEMBL11742496 0.81
SCHEMBL16940181 0.81 MEN1 (0.32) ALDH1A1TDP1FFAR3MEN1KMT2A
SCHEMBL2423505 0.77
SCHEMBL1245998 0.74
SCHEMBL4887740 0.74
SCHEMBL8712062 0.72 CES2 (0.50) ALDH1A1TDP1FFAR3MEN1KMT2A
SCHEMBL1880913 0.72
SCHEMBL8057560 0.72
SCHEMBL5660160 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196936-A1 POLYNUCLEOTIDE CANCER VACCINE COMPOSITIONS AND METHODS OF USING THE SAME Imunon, Inc. (US) 2023-10-12 WO claimed
WO-2023196935-A1 POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME Imunon, Inc. (US) 2023-10-12 WO claimed
EP-4221739-A1 POLYNUCLEOTIDE VACCINES AND METHODS OF USING THE SAME Imunon, Inc. (US) 2023-08-09 EP claimed
EP-3597717-B1 COATING PROCESS USING A POLYSULFIDE SEALANT COMPRISING CORE-SHELL PARTICLES BOEING CO (US) 2021-03-31 EP claimed
EP-3078718-B1 CORE-SHELL PARTICLES, COMPOSITIONS INCORPORATING THE CORE-SHELL PARTICLES AND METHODS OF MAKING THE SAME BOEING CO (US) 2019-08-14 EP claimed
US-9856359-B2 Core-shell particles, compositions incorporating the core-shell particles and methods of making the same THE BOEING COMPANY (US) 2018-01-02 US claimed
US-20160300646-A1 CORE-SHELL PARTICLES, COMPOSITIONS INCORPORATING THE CORE-SHELL PARTICLES AND METHODS OF MAKING THE SAME THE BOEING COMPANY 2016-10-13 US claimed
EP-3078718-A2 CORE-SHELL PARTICLES, COMPOSITIONS INCORPORATING THE CORE-SHELL PARTICLES AND METHODS OF MAKING THE SAME The Boeing Company (US) 2016-10-12 EP claimed
EP-2934909-A1 RUBBER COMPOSITION COMPRISING CELLULOSE Compagnie Générale des Etablissements Michelin (FR) 2015-10-28 EP claimed
EP-2934910-A2 RUBBER COMPOSITION COMPRISING CELLULOSE Compagnie Générale des Etablissements Michelin (FR) 2015-10-28 EP claimed
WO-2014096192-A2 RUBBER COMPOSITION COMPRISING CELLULOSE COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2014-06-26 WO claimed
WO-2014096188-A1 RUBBER COMPOSITION COMPRISING CELLULOSE COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2014-06-26 WO claimed
US-8344177-B2 Albumin binding molecules and uses thereof PHILOCHEM AG (CH) 2013-01-01 US claimed
US-20100172844-A1 ALBUMIN BINDING MOLECULES AND USES THEREOF PHILOCHEM AG (CH) 2010-07-08 US claimed
EP-2094647-A2 ALBUMIN BINDING MOLECULES AND USES THEREOF Philochem AG (CH) 2009-09-02 EP claimed
WO-2008053360-A2 ALBUMIN BINDING MOLECULES AND USES THEREOF PHILOCHEM AG (CH) 2008-05-08 WO claimed
CN-116916949-A Polynucleotide vaccine and methods of use thereof 伊穆农股份有限公司 2023-10-20 CN disclosed
WO-2023196935-A1 POLYNUCLEOTIDE VACCINE FORMULATIONS AND METHODS OF USING THE SAME Imunon, Inc. (US) 2023-10-12 WO disclosed
EP-0704460-A1 PROCESS FOR PRODUCING POLYMER TERMINATED WITH OPTIONALLY PROTECTED FUNCTIONAL GROUP KURARAY CO., LTD. (JP) 1996-04-03 EP disclosed
US-4399075-A Process for producing chlorinated phenoxytoluene derivatives ASAHI CHEMICAL COMPANY, LIMITED (JP) 1983-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172844-A1 ALBUMIN BINDING MOLECULES AND USES THEREOF ALB, FABP1, FABP2 ALDH1A1 2026/4885TDP1 4688/4885FFAR3 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.